Search details
1.
Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?
PLoS One
; 18(2): e0281726, 2023.
Article
in English
| MEDLINE | ID: mdl-36827283
2.
Thromboembolism in nephrotic syndrome: controversies and uncertainties.
Res Pract Thromb Haemost
; 7(6): 102162, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37680313
3.
Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen.
Glomerular Dis
; 3(1): 88-97, 2023.
Article
in English
| MEDLINE | ID: mdl-37113496
4.
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications.
Glomerular Dis
; 3(1): 266-274, 2023.
Article
in English
| MEDLINE | ID: mdl-38054033
5.
PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy.
Kidney Int Rep
; 8(8): 1605-1615, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37547510
6.
Time for a relook? An update on primary membranous nephropathy incidence in a large UK cohort.
Clin Kidney J
; 17(4): sfae066, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38577270
Results
1 -
6
de 6
1
Next >
>>